Safety, Tolerability, Immunogenicity, Pharmacodynamic Characteristics, and Preliminary Anti-tumor Activity of Personalized Cancer Vaccines Alone and in Combination With Toripalimab in Participants With Resected NSCLC

Clinical trial NCT07683832 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07683832
Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Status: NOT_YET_RECRUITING
Phase: Early Phase 1
Study type: INTERVENTIONAL

Non-Small Cell Lung Cancer NSCLC

Start date: 2026-07-28
Primary completion: 2028-12-31
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.